Objective To explore the effect
of Jinsang Sanjie capsules in patients with reflux pharyngitis. Methods A
total of 94 patients with reflux pharyngitis in Qingyang Hospital of
Traditional Chinese Medicine from August 2020 to July 2021 were selected for
retrospective study. According to different treatment plans, they were divided
into a control group and an observation group, with 47 cases in each group. There
were 22 males and 25 females in the control group, aged (46.51±8.79) years;
there were 19 males and 28 females in the observation group, aged (45.51±7.79)
years. The control group was treated with rabeprazole and mosapride, and the
observation group was additionally treated with Jinsang Sanjie capsules on the
basis of the control group. The total effective rates, clinical symptom scores,
serum inflammatory factors levels [interleukin-2 (IL-2), IL-8, and tumor
necrosis factor-α (TNF-α)], plasma gastrointestinal hormones levels [vasoactive
intestinal peptide (VIP), motilin (MTL), and gastrin (GAS)], and adverse
reactions of the two groups were observed. The measurement data were tested by
independent sample t test or paired t test and the count data by χ2 test. Results The total effective
rate of the observation group was 95.74% (45/47), higher than that of the
control group [82.98% (39/47)] (P<0.05).
After treatment, the scores of cough, dysphagia, sticky throat, heartburn and
acid reflux, and heating in the observation group were (0.51±0.14) points,
(0.32±0.17) points, (0.31±0.12) points, (0.42±0.14) points, and (0.61±0.28)
points, respectively, lower than those in the control group [(0.66±0.23)
points, (0.41±0.22) points, (0.49±0.17) points, (0.71±0.29) points, and
(0.81±0.31) points] (all P<0.05).
After treatment, the levels of IL-8, TNF-α, and VIP in the observation group
were (12.17±1.21) ng/L, (8.31±1.07) ng/L, and (16.88±2.19) ng/L, respectively,
lower than those in the control group [(19.31±2.75) ng/L, (13.10±1.26) ng/L,
and (20.86±2.31) ng/L], and the levels of IL-2, MTL, and GAS were (8.43±1.96)
μg/L, (320.25±46.14) ng/L, and (162.96±23.15) ng/L, respectively, higher than
those in the control group [(6.31±1.05) μg/L, (281.29±42.56) ng/L, and (133.57±18.46)
ng/L] (all P<0.05). The rate of
adverse reactions in the observation group was 4.26% (2/47), and there was no
statistically significant difference compared with 8.51% (4/47) in the control
group (P>0.05). Conclusion Jinsang Sanjie capsules combined with rabeprazole and mosapride has
a significant effect in the treatment of reflux pharyngitis, which can
effectively improve the patients' symptoms and reduce the levels of
inflammatory factors.